Intraperitoneal therapy of ovarian cancer

Oncologist

Volumn 1, Issue 1-2, 1996, Pages 18-21

  Markman, Maurie ^a,b  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Cancer chemotherapy; Carboplatin; Cisplatin; Interferon ; Interferon ; Interleukin 2; Intraperitoneal chemotherapy; Ovarian cancer; Paclitaxel

Indexed keywords

EID: 0001847880     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.1-1-18     Document Type: Article

References (14)

1. Markman M. Intraperitoneal anti-neoplastic agents for tumors principally confined to the peritoneal cavity. Cancer Treat Rev 1986;13:219-242.
2. Markman M. Intraperitoneal chemotherapy. Semin Oncol 1991;18(suppl 3):248-254.
3. Dedrick RL, Myers CE, Bungay PM et al. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 1978;62:1-9.
4. Pfeifle CE, Howell SB, Markman M et al. Totally implantable system for peritoneal access. J Clin Oncol 1984;2:1277-1280.
5. Kaplan RA, Markman M, Lucas WE et al. Infectious peritonitis in patients receiving intraperitoneal chemotherapy. Am J Med 1985;78:49-53.
6. Davidson SA, Rubin SC, Markman M et al. Intraperitoneal chemotherapy: analysis of complications with an implantable subcutaneous port and catheter system. Gynecol Oncol 1991;41:101-106.
7. Markman M, Reichman B, Hakes T et al. Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J Clin Oncol 1991:9:1801-1805.
8. Markman M. Regional antineoplastic drug delivery in the management of malignant disease. Baltimore: The Johns Hopkins University Press, 1991.
9. Berek JS, Markman M. Intraperitoneal administration of biologic agents. Int J Gynecol Cancer 1992;1:26-29.
10. Markman M, Berek JS. Intraperitoneal administration of the biologic agents tumor necrosis factor, gamma-interferon and interleukin-2. Int J Gynecol Cancer 1992;1:30-34.
11. Alberts DS, Liu PY, Hannigan EV et al. Phase III study of intraperitoneal cisplatin/intravenous cyclophosphamide vs. IV cisplatin/IV cyclophosphamide in patients with optimal disease stage III ovarian cancer: a SWOG-GOG-ECOG intergroup study (INT 0051). Proc Am Soc Clin Oncol 1995;14:273a.
12. Rowinsky EK, Donehower RC. Paclitaxel. N Engl J Med 1995:332:1004-1014.
13. Markman M, Rowinsky E, Hakes T et al. Phase I trial of intraperitoneal Taxol®: a Gynecologic Oncology Group study. J Clin Oncol 1992;10:1485-1491.
14. Francis P, Rowinsky E, Schneider J et al. Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot study. J Clin Oncol 1995;13:2961-2967.